Business
AI summaryCinclus Pharma Holding AB (publ) is a clinical-stage pharmaceutical company developing small molecules for gastric acid-related diseases in China. Its lead candidate, linaprazan glurate, is a potassium-competitive acid blocker that has completed a Phase II trial in gastroesophageal reflux disease, and the company is also pursuing a combination of linaprazan glurate with antibiotics, in preclinical work against the peptic-ulcer bacterium Helicobacter pylori. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
